Data sourced from NSE · Compiled by IPO Ji · IPO subscription data last updated
Total 2.31x·QIB 15.94x·NII 1.41x·Individual 2.92x
Based on individual subscription by applications (2.92×), approximately 1 in 3 individual applications may receive an allotment. Final allotment is decided by the registrar’s computerised lottery.
Bio Medica Laboratories Limited SME IPO was subscribed 2.31x in total when bidding closed on May 25, 2026, with 15.94x in the QIB category, 1.41x in NII, 2.92x in individual across NSE. The issue is oversubscribed, indicating healthy demand across investor categories. The issue ran from May 21, 2026 to May 25, 2026 at a price band of ₹132–₹139 per share. Allotment was finalised on May 26, 2026.
| Category | Offer | Applied | Times |
|---|---|---|---|
| QIBs | 36000 | 574000 | 15.94 |
| NIIs | 1755000 | 2475000 | 1.41 |
| BNIIs (>10L) | 1170000 | 1193000 | 1.02 |
| SNIIs (<10L) | 585000 | 1282000 | 2.19 |
| Individual | 1792000 | 5226000 | 2.92 |
| Total | 3583000 | 8275000 | 2.31 |
| Total Applications3076 approx. |
|||
| Category | Reserve | Applied | Times |
|---|---|---|---|
| BNIIs (>10L) | 390 | 35 | 0.09 |
| SNIIs (<10L) | 195 | 422 | 2.16 |
| Individual | 896 | 2613 | 2.92 |
| Total Applications3076 approx. |
|||
| Category | Offered | Demand | Times |
|---|---|---|---|
| QIBs | 0.5 | 7.98 | 15.94 |
| FIIs | - | 7.98 | - |
| DIIs | - | 0.00 | - |
| Mutual Funds | - | 0.00 | - |
| Others | - | 0.00 | - |
| NIIs | 24.39 | 34.4 | 1.41 |
| BNIIs (>10L) | 16.26 | 16.58 | 1.02 |
| SNIIs (<10L) | 8.13 | 17.82 | 2.19 |
| Individual | 24.91 | 72.64 | 2.92 |
| TOTAL | 49.8 | 115.02 | 2.31 |
| As on | QIB |
NII
bHNI
sHNI
|
Individual | Total |
|---|---|---|---|---|
|
Day 1
21 May 2026
5:00 PM
|
15.94x |
0.03x
0.01x
0.06x
|
1.09x | 0.72x |
|
Day 2
22 May 2026
5:00 PM
|
15.94x |
0.39x
0.35x
0.46x
|
1.42x | 1.06x |
|
Day 3
25 May 2026
5:00 PM
|
15.94x |
1.41x
1.02x
2.19x
|
2.92x | 2.31x |
Anticipated subscription based on the number of applications received (an alternative to the shares-based figures above), sourced from NSE.
| Category | Times (by applications) |
|---|---|
| bHNI | 0.09x |
| sHNI | 2.16x |
| Individual | 2.92x |
Because Bio Medica Laboratories closed oversubscribed, applicants were not guaranteed full allotment. In oversubscribed issues, shares are allotted according to the applicable category and exchange rules, so applicants are not guaranteed full allotment once an issue is oversubscribed. The number of times each category is subscribed is one indicator of demand, alongside the company's fundamentals and the broader market.
A high subscription figure reflects strong demand but does not guarantee a premium listing, and a low figure does not guarantee a discount. This page is for information only and is not investment advice. Investors should read the company's prospectus and consult a SEBI-registered adviser before making any decision.
IPO subscription status shows how many times an issue has been applied for, compared with the shares on offer, broken down by Qualified Institutional Buyers (QIB), Non-Institutional Investors (NII), and the Retail or SME Individual Investor category. A figure of "2x" means investors applied for twice the shares available. See how IPO subscription works and track all live IPOs →
Data Source: The above information / data is sourced from National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) websites and is subject to change in real time. For latest information / data, please refer to the respective websites.
Purpose: The information / data provided herein is for informational purposes only and is provided by ipoji.com on "AS IS" and "AS AVAILABLE" basis and without warranty, express or implied.
Accuracy: ipoji.com does not warrant the accuracy, adequacy or completeness of the information you obtain through the above websites.
Liability: ipoji.com shall not be liable in any way for any discrepancies, errors, omissions, losses or damage. ipoji.com, including its affiliates and its directors, staff and employees, shall not be liable for any loss, damage of any kind, including but not limited to direct, indirect, punitive, exemplary, consequential damages and lost profits arising in any way out of the use of information / data obtained through the said websites.
User Responsibility: The recipient alone is fully responsible / liable for any decision made based on this information / data. All recipients, before relying on the said information, should do their own research and seek appropriate professional advice.